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Dialogues, dilemmas, and disclosures: genomic research
and incidental findings
Lynn W. Bush, PhD, MA1 and Karen H. Rothenberg, JD, MPA2,3
As the evolution of next-generation sequencing into clinical
research and practice progresses exponentially, so too will
the discovery of incidental findings and ethical complexities
accelerate.1,2 Controversial issues abound—such as determining whether, what, to whom, and how much genomic information should be disclosed to individual participants and
their families.3,4 We believe that the research and bioethical
communities need to engage in further dialogue, reflecting
on these unresolved dilemmas to enrich the policy process.
To illuminate some of the personal and familial challenges surrounding the reporting of genomic findings, we composed It’s
So Complicated! (Supplementary Material online)—the sequel
to It’s Not That Simple!5 highlighting the informed consent process in our series of original dramatic vignettes designed to foster understanding of the ethical, psychological, legal, and social
implications of genomic research.6 Feedback from stagings of
Complicated (selections below) at the 2011 American Society
for Bioethics and Humanities conference, the National Human
Genome Research Institute, and universities in the United States
and Australia parallel experiences with Not Simple7—supporting
this creative approach as a vehicle to enhance the appreciation for
the complexity of sharing next-generation sequencing results.
It’s So Complicated! brings to life the dialogues and dilemmas
elicited by disclosing incidental findings through the lens of our
recurring characters, Dr Hardy and the Friedman family—a
mother, her 19-year-old son and 16-year-old daughter (both
symptomatic with an autosomal recessive disorder), and Sam,
their unaffected 9-year-old sibling—as they return to the geneticist after participating in genomic research. Along with exploring reactions toward results generated from the genomic study,
the vignette illustrates the inherent tensions of the researcher/
clinician sharing findings with family members spanning generations, each with different values and affective responses.
The psychological, economic, and social risks of revealing genomic information that is even suggestive of disease to
healthy participants must be carefully weighed against medical
benefits. Although the lengthy consent form language subtly
alludes to the possibility of learning secondary results, for many
individuals it is as if the potential for discovering incidentals
with whole exome/genome sequencing is highly remote. The
element of surprise can be emotionally unsettling, particularly

when neither families nor professionals fully anticipate the
range of findings that will be routinely discovered upon the
application of this powerful technology. Further complicating
the discovery of incidental findings, it will often be the case
that the original question for which genomic study was indicated may go unanswered:
dr. HARDY:	Well, Amy, as for Bobby and your disorder,
unfortunately nothing conclusive was uncovered…[however] we learned several things
that I must discuss with some of you…findings unrelated to what we were looking for.
AMY:	Huh? How can you find something if you
weren’t looking for it?...
MOM:	What do you mean learn my results—I’m not
sick!...Am I ?
Neither the researcher nor the participants can predict who
will bear the burden and distress from the return of unanticipated findings. Implications need to be considered for individuals who previously identified themselves as healthy as well
as those defined by their genetic condition. Moreover, there is
little consensus regarding under what circumstances, if any, a
consent form’s request “not to know” may go unhonored:
DR HARDY:	You mentioned last visit that you thought
the stress…was making you forgetful…
I’d like to recommend…a neurologist….
There were certain findings…that hint at
the possibility…and only a possibility…of
a susceptibility…to something…and we
want to check it out more clearly….
MOM:	You’re not implying that I’m going to go
senile when I am 80 years old…. I told
you I don’t want to know that stuff…
Alzheimer’s is for old people. I’ll worry
about that when I get old. (exits)
DR HARDY:	(to self): Assuming the CLIA test result confirms my finding, at least it will be the neurologist having to tell her she very likely has
early-onset AD.
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The judgment regarding the disclosure of secondary results
attained in genomic research remains controversial, and the
need to clarify definitions such as variable penetrance and susceptibility is essential. There is great debate as to what revelations
constitute urgency for disclosure and who should decide, as well
as what findings are deemed clinically relevant, actionable, or
predictable. Caution is also advised to avoid misinterpretation
of susceptibility with a diagnosis of disease, especially when it
is low risk.
DR HARDY:	We found some….extra….concerns….. The
genome analysis shows that you carry the
BRCA mutation….that doesn’t necessarily
mean you’ll get breast cancer; it only indicates a susceptibility….the possibility for
getting a disease. Indeed, your risk is quite
low, only about 6% lifetime risk for breast
cancer…..
BOBBY:	I think you confused my results with Amy’s
or Mom’s—that’s a girl’s disease…. Do
Amy and Sam have breast cancer too? And
Mom?
DR HARDY:	First off, please let me be clear that I am not
saying you have breast cancer. Only that you
carry the genetic mutation associated with
the possibility for developing the disease. We
call that higher risk; not definitely getting the
disease…..
BOBBY:
(blurts to Mom) I have breast cancer!!!
DR HARDY:	Please remember you don’t have breast cancer now and might never even get it. It’s only
a potential future possibility…. a slight future
possibility.
MOM:	Oh my, is this some nightmare? We came
here for you to tell us results that can help my
kids’ disease, and now you’re telling Bobby
he’ll die from breast cancer instead?
Next-generation sequencing raises challenges when otherwise
healthy children are faced with findings that threaten their
identity and raise novel concerns about their future.8 The age
range of the Friedmans highlights the additional responsibility required when considering sharing genomic information
attained from families that include minors. As investigations
involving children and adolescents engender even more complex ethical and psychological challenges,9 the need for heightened sensitivity by professionals becomes magnified, as does
the unsettling nature for researchers. Differential approaches
must be weighed not only to consider whether, but to whom,
results may be disclosed:10
DR HARDY:	I need to discuss something else with you…
about Sam…about something else that we
found in the genomic testing…related to her
heart.
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MOM:	You must be mistaken…she’s a really good
athlete…on our Y’s swim team….
DR HARDY:	There’s a condition called long QT syndrome…we can’t perfectly predict when or
which patients with the genetic predisposition…will have an arrhythmia associated
with sudden cardiac arrest. So I need to share
the seriousness of this with Sam and tell her
we very strongly recommend that competitive athletics be forsaken.
MOM:	Oh no, you can’t tell her anything is wrong….
And anyway, remember you told me these
tests aren’t certain!
DR HARDY:	I must inform her so she’ll give up competitive sports…especially competitive swimming. (gets Sam and explains)….
SAM:	(sobbing) But you’re telling me I can’t do
what I do best….
MOM:	I can’t believe this is happening…. Sam was
my healthy kid this morning….
DR HARDY:	(reflective) I am so sorry…. it’s so compli
cated!
Based on our experiences, the characters portrayed in the
vignette highlight the complexity of emotions, reactions, and
implications of disclosure of genomic information to family
members spanning generations. As one physician witnessing the play at the 2011 American Society for Bioethics and
Humanities conference, “Medicine is complicated, and the
family is under psychological stress which impedes them from
hearing and integrating the information.”
In fact, interprofessional groups who played the characters
expressed similar thoughts to those of the audience regardless of their geographical home or discipline. For example, a
bioethicist portraying the role of the doctor wrote that this
vignette “drew me into the head of Dr. Hardy to appreciate the
challenge he was facing in attempting to disclose the incidental findings to the different family members. Reading his lines
evoked his nervousness in me, which allowed me to convey the
awkwardness of the situation.” A physician playing Sam noted,
“I saw how the doctor here was also in distress, with a lot of
uncertainty regarding the incidental finding of this 9-year-old
child, as he tries to explain that he really doesn’t know what
the consequences will be; this uncertainty is not well perceived
by the family for we cannot talk of outcome but just make
approximations.”
The receptivity to exploring these complex ethical dilemmas
through creative avenues such as dramatic vignettes suggests
value in bringing to life the challenges faced by participants
and professionals in order to enhance the discourse and policy
process. As one member of the audience remarked, “By having the play highlight just how jarring it can be for a family—
and a doctor—it really showed us how essential it is that we
decide ahead of time what incidental findings actually should
be reported.”
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